Malignant Tumor
51
11
13
17
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.9%
2 terminated out of 51 trials
89.5%
+2.9% vs benchmark
4%
2 trials in Phase 3/4
0%
0 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (51)
Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis
Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors
First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2
Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
Rehabilitation Outcomes Study
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
Effectiveness of Central Oncology Navigation and the Use of an ORN
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Impact of Family-Centered Empowerment on Caregivers of Children with Cancer: a Quasi-Experimental Study Protocol
XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy